Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport extension study in adult lower limb spasticity after stroke or traumatic brain injury
2009-017723-26Phase 3Completed
- Sponsor
- Ipsen
- Start
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in lower extremity spasticity and spastic hemiparesis, sponsored by Ipsen. Primary endpoint: Long-term safety. Started Feb 2011; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
lower extremity spasticityspastic hemiparesis
Beyond the preview
Go deeper on 2009-017723-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017723-26.